We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).
- Authors
Chen, Yunxin; Gopalakrishnan, Sathish Kumar; Ooi, Melissa; Sultana, Rehena; Lim, Li Hui; Grigoropoulos, Nicholas; Ong, Shin Yeu; Xu, Mingge; SGHMM1 Investigators; Teh, Ee Mei; Tan, Melinda; Ng, Lawrence; Lee, Yuh Shan; Phipps, Colin; Lim, Francesca Lorraine W. Y.; Hwang, William; Chng, Wee Joo; Goh, Yeow Tee; Nagarajan, Chandramouli
- Abstract
In fact, being able to provide the long-term outcomes of such an MRD-adapted treatment strategy (with the caveat of the single point MRD and a small number of patients) is a motivation for us to present these results. Hence, we considered that giving no maintenance therapy for any given group of myeloma patients as a reflection of our practice and not disadvantaging patients specifically for the purpose of the trial. Between 29 October 2014 and 11 September 2017, 32 patients were screened and 30 eligible patients received trial treatment. Secondly, the routine standard of care in our Institutions at the time of study commencement (and till recently) was induction and consolidation with only very few patients in our practice being able to receive maintenance (due to cost considerations and patient preference).
- Subjects
STEM cell transplantation; CYCLOPHOSPHAMIDE; NON-ST elevated myocardial infarction; POSTOPERATIVE nausea &; vomiting
- Publication
Blood Cancer Journal, 2021, Vol 11, Issue 9, p1
- ISSN
2044-5385
- Publication type
Letter
- DOI
10.1038/s41408-021-00544-x